These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 17324242)

  • 41. Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia.
    Staner C; Joly F; Jacquot N; Vlasova ID; Nehlin M; Lundqvist T; Edenius C; Staner L
    Curr Med Res Opin; 2010 Jun; 26(6):1423-31. PubMed ID: 20397964
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study.
    Cluydts R; Peeters K; de Bouyalsky I; Lavoisy J
    J Int Med Res; 1998; 26(1):13-24. PubMed ID: 9513073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zolpidem: clinical experience in psychiatric settings.
    Undén M
    Pol J Pharmacol; 1994; 46(5):483-5. PubMed ID: 7894539
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-benzodiazepine hypnotics and older adults: what are we learning about zolpidem?
    Levy HB
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):5-8. PubMed ID: 24308787
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Abuse potential during use and withdrawal psychosis after treatment with the hypnotic zolpidem (Stilnoct)].
    Bruun TG
    Ugeskr Laeger; 1993 Aug; 155(35):2711-3. PubMed ID: 7786333
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [First meeting of the French CEIP (centres d'évaluation et d'information sur la pharmacodépendance). Assessment of the abuse and pharmacodependence potential during drug development].
    Micaleff J; Jolliet P; Victorri-Vigneau C; Mallaret M; Richard N; Haramburu F; Lapeyre-Mestre M
    Therapie; 2008; 63(1):55-65. PubMed ID: 18387277
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Zolpidem dependence. Zolpidem dependence is frequent, and should be discussed with patients.
    Prescrire Int; 2008 Jun; 17(95):114. PubMed ID: 18634166
    [No Abstract]   [Full Text] [Related]  

  • 48. Zolpidem dependence in a patient with former polysubstance abuse.
    Bottlender R; Schütz C; Möller HJ; Soyka M
    Pharmacopsychiatry; 1997 May; 30(3):108. PubMed ID: 9211573
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Zolpidem-induced psychosis.
    Markowitz JS; Brewerton TD
    Ann Clin Psychiatry; 1996 Jun; 8(2):89-91. PubMed ID: 8807033
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia.
    Roger M; Attali P; Coquelin JP
    Clin Ther; 1993; 15(1):127-36. PubMed ID: 8458042
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The safety and tolerability of zolpidem--an update.
    Darcourt G; Pringuey D; Sallière D; Lavoisy J
    J Psychopharmacol; 1999; 13(1):81-93. PubMed ID: 10221362
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Zolpidem-induced sneezing: A case report of positive rechallenge.
    Amraei R; Parsa A; Babaeian M
    Medicine (Baltimore); 2018 Mar; 97(9):e9918. PubMed ID: 29489694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toward evidence-based prescribing at end of life: a comparative review of temazepam and zolpidem for the treatment of insomnia.
    Bain KT; Weschules DJ; Knowlton CH; Gallagher R
    Am J Hosp Palliat Care; 2003; 20(5):382-8. PubMed ID: 14529041
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modest abuse-related subjective effects of zolpidem in drug-naive volunteers.
    Licata SC; Mashhoon Y; Maclean RR; Lukas SE
    Behav Pharmacol; 2011 Apr; 22(2):160-6. PubMed ID: 21301324
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravenous zolpidem injection in a zolpidem abuser.
    Hsu WY; Chiu NY
    Pharmacopsychiatry; 2013 May; 46(3):121-2. PubMed ID: 23093474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Second meeting of the French CEIP (Centres d'Evaluation et d'Information sur la Pharmacodépendance). Part I: how to evaluate and prevent the abuse and dependence on hypnotic/anxiolytic drugs?
    Micallef-Roll J; Lapeyre-Mestre M;
    Therapie; 2009; 64(6):355-64. PubMed ID: 20025838
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dependence, misuse, and beliefs regarding use of hypnotics by elderly psychiatric patients taking zolpidem, estazolam, or flunitrazepam.
    Yen CF; Ko CH; Chang YP; Yu CY; Huang MF; Yeh YC; Lin JJ; Chen CS
    Asia Pac Psychiatry; 2015 Sep; 7(3):298-305. PubMed ID: 25296384
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ineffectiveness of intermittent zolpidem.
    Kripke DF
    Sleep Med Rev; 2003 Apr; 7(2):193; author reply 195-6. PubMed ID: 12628218
    [No Abstract]   [Full Text] [Related]  

  • 59. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients.
    Walsh JK; Soubrane C; Roth T
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):44-57. PubMed ID: 18165461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Withdrawal psychosis and zolpidem].
    Haastrup S
    Ugeskr Laeger; 1993 Dec; 155(51):4196. PubMed ID: 8273252
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.